Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation
Open accessPreprint — published as 10.1016/j.cell.2021.04.025 · Paper page
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
We identified a novel SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains. The variant carries 3 mutations in the spike protein, including an L452R substitution. Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants. Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California associated with decreased antibody neutralization warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This variant showed reduced resistance to neutralization by convalescent (4–6.7-fold) and post-vaccination sera (2–2.9-fold) against this variant [38, 39].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [38]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
Posterior summarization in Bayesian phylogenetics using tracer 1.7
Rambaut, A., Drummond, A. J., Xie, D., Baele, G., & Suchard, M. A. (2018) · Systematic Biology · doi:10.1093/sysbio/syy032 · Cited by 11,159
Bayesian Phylogenetics with BEAUti and the BEAST 1.7
Drummond, A. J., Suchard, M. A., Xie, D., & Rambaut, A. (2012) · Molecular Biology and Evolution · doi:10.1093/molbev/mss075 · Cited by 10,063 · cited 3×
“The resulting maximum clade credibility (MCC) tree was generated using 530 TreeAnnotator v.2.6.3 (Drummond et al., 2012) and visualized using FigTree v.1.4.4 531 (Rambaut, 2021).”
MethodInfluentialStructure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
GISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039 · cited 7×
“508 Multiple sequence alignment of 6 B.1.427/B.1.429 genomes and the Wuhan Hu-1 509 prototypical genome (GISAID ID: EPI_ISL_402125, GenBank accession number 510 MN908947) was performed using the MAFFT aligner v7.”
MethodInfluentialA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Mendenhall, I. (2015) · doi:10.6084/m9.figshare.1451280.v1 · Cited by 1,266
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
Quick, J., Grubaugh, N. D., Pullan, S. T., Claro, I. M., Smith, A. D., Gangavarapu, K., Oliveira, G., Robles-Sikisaka, R., Rogers, T. F., Beutler, N. A., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2017.066 · Cited by 1,190
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · cited 1×
“…have reported that 82 the E484K mutation in particular may confer resistance to antibody neutralization (Cole 83 et al., 2021; Wang et al., 2021; Wibmer et al., 2021; Wu et al., 2021; Xie et al., 2021), 84 potentially resulting in decreased efficacy of currently available vaccines (Liu et al.,…”
BackgroundQuick, J., Grubaugh, N., Pullan, S., et al. (2017) · Nature Protocols · doi:10.1101/098913 · Cited by 1,129
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Self-citationSARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900
Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W., Lam, E. C., Denis, K. J. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.14.21251704 · Cited by 781
Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725
Avanzato, V. A., Matson, M. J., Seifert, S. N., Pryce, R., Williamson, B. N., Anzick, S. L., Barbian, K., Judson, S. D., Fischer, E. R., Martens, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.049 · Cited by 716
Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651
Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
SARS-CoV-2 spike D614G change enhances replication and transmission
Zhou, B., Thao, T. T. N., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A., King, J., Steiner, S., Kelly, J. N., et al. (2021) · Nature · doi:10.1038/s41586-021-03361-1 · Cited by 538 · cited 1×
“Among numerous SARS-CoV-2 variants now circulating 65 globally, those harboring a D614G mutation have predominated since June of 2020 66 (Korber et al., 2020), possibly due to enhanced viral fitness and transmissibility (Hou et 67 al., 2020; Plante et al., 2020; Zhou et al., 2021).”
BackgroundNeutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537
SARS-CoV-2 variants and ending the COVID-19 pandemic
Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S. S. A., & Sridhar, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00370-6 · Cited by 519
Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., et al. (2021) · Science · doi:10.1126/science.abe9728 · Cited by 488
Mutations Strengthened SARS-CoV-2 Infectivity
Chen, J., Wang, R., Wang, M., & Wei, G.-W. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.07.009 · Cited by 466
Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412
Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Emergence of a Novel SARS-CoV-2 Variant in Southern California
Zhang, W., Davis, B. D., Chen, S. S., Sincuir Martinez, J. M., Plummer, J. T., & Vail, E. (2021) · JAMA · doi:10.1001/jama.2021.1612 · Cited by 371 · cited 1×
“88 In January 2021, we and others independently reported the emergence of a 89 novel variant in California carrying an L452R mutation in the RBD of the spike protein 90 (CDPH, 2021; Zhang et al., 2021).”
BackgroundNeutralizing antibody titres in SARS-CoV-2 infections
Lau, E. H. Y., Tsang, O. T. Y., Hui, D. S. C., Kwan, M. Y. W., Chan, W.-H., Chiu, S. S., Ko, R. L. W., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20247-4 · Cited by 333
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Washington, N. L., Gangavarapu, K., Zeller, M., Bolze, A., Cirulli, E. T., Schiabor Barrett, K. M., Larsen, B. B., Anderson, C., White, S., Cassens, T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.052 · Cited by 329
Self-citationGenomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California
Deng, X., Gu, W., Federman, S., du Plessis, L., Pybus, O. G., Faria, N. R., Wang, C., Yu, G., Bushnell, B., Pan, C.-Y., et al. (2020) · Science · doi:10.1126/science.abb9263 · Cited by 262 · cited 1×
“497 498 Genome Assembly and Variant Calling 499 Genome assembly of viral reads and variant calling were performed using an in-500 house developed bioinformatics pipeline as previously described (Deng et al., 2020).”
MethodSelf-citationAn integrated national scale SARS-CoV-2 genomic surveillance network
(2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30054-9 · Cited by 261
Samuel, R. M., Majd, H., Richter, M. N., Ghazizadeh, Z., Zekavat, S. M., Navickas, A., Ramirez, J. T., Asgharian, H., Simoneau, C. R., Bonser, L. R., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.11.009 · Cited by 261
Self-citationIncreased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
Davies, N. G., Jarvis, C. I., CMMID COVID-19 Working Group, Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., & Keogh, R. H. (2021) · medRxiv · doi:10.1101/2021.02.01.21250959 · Cited by 211
Covid-19: The E484K mutation and the risks it poses
Wise, J. (2021) · BMJ · doi:10.1136/bmj.n359 · Cited by 211 · cited 2×
“, 2021), 84 potentially resulting in decreased efficacy of currently available vaccines (Liu et al., 85 2021; Wise, 2021).”
BackgroundOn the evolutionary epidemiology of SARS-CoV-2
Day, T., Gandon, S., Lion, S., & Otto, S. P. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.031 · Cited by 205
Case, J., Rothlauf, P. W., Chen, R. E., et al. (2020) · bioRxiv · doi:10.1101/2020.05.18.102038 · Cited by 162
Klimstra, W. B., Tilston-Lunel, N. L., Nambulli, S., Boslett, J., McMillen, C. M., Gilliland, T., Dunn, M. D., Sun, C., Wheeler, S. E., Wells, A., et al. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001481 · Cited by 137
Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2020) · doi:10.1101/2020.11.06.372037 · Cited by 135
Teng, S., Sobitan, A., Rhoades, R. E., Liu, D., & Tang, Q. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa233 · Cited by 125 · cited 1×
“240 Prior studies have suggested that the L452R mutation may stabilize the 241 interaction between the spike protein and its human ACE2 receptor and thereby 242 increase infectivity (Chen et al., 2020; Teng et al., 2020).”
BackgroundHu, J., Peng, P., Wang, K., Fang, L., Luo, F.-Y., Jin, A.-S., Liu, B.-Z., Tang, N., & Huang, A.-L. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00648-1 · Cited by 112 · cited 1×
“…with L452R mutation is slightly 157 lower than the increase observed with the N501Y mutation (11.4 to 30.9-fold increase in 158 293T cells and 23.5 to 37.8-fold increase in HAO relative to D614G alone), which has 159 previously been reported to increase pseudovirus entry (Hu et al., 2021).”
BackgroundInfluentialWashington, N., Gangavarapu, K., Zeller, M., et al. (2021) · medRxiv · doi:10.1101/2021.02.06.21251159 · Cited by 106
Estimates of serial interval for COVID-19: A systematic review and meta-analysis
Rai, B., Shukla, A., & Dwivedi, L. K. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2020.08.007 · Cited by 97
Zune, A. L. D., Olwal, C. O., Beyeme, T. S., & Paemka, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01448 · Cited by 73
A genomics network established to respond rapidly to public health threats in South Africa
Msomi, N., Mlisana, K., de Oliveira, T., Msomi, N., Mlisana, K., Willianson, C., Bhiman, J. N., Goedhals, D., Engelbrecht, S., Van Zyl, G., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30116-6 · Cited by 48
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibilityPreprint
Shi, P., Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., et al. (2020) · bioRxiv · doi:10.21203/rs.3.rs-70482/v1 · Cited by 42
Gorensek, M. J. (1989) · Dermatologia clinica · doi:10.1016/s0733-8635(18)30605-3 · Cited by 33
Wang, S., Sakhatskyy, P. V., Chou, T.-H. W., & Lu, S. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.03.008 · Cited by 30
The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2
Drew, R., O'Donnell, S. T., LeBlanc, D., McMahon, M., & Natin, D. (2020) · Diagnostic microbiology and infectious disease · doi:10.1016/j.diagmicrobio.2020.115130 · Cited by 30
Case, J. B., Rothlauf, P. W., Chen, R. E., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3606354 · Cited by 19
Wilson, D. R. (1992) · Acta Biotheoretica · doi:10.1007/bf00046552 · Cited by 8
Arıkan, A., & Sayan, M. (2022) · Diagnostics · doi:10.3390/diagnostics12112869 · Cited by 3
Research works printed but not linked: 2
- Chand, M. , Hopkins, S. , Dabreara, G. , Allen, H. , Lamagni, T. , Edeghere, O. , Achison, C. , Myers, R. , Barclay, W. , Ferguson, N. , et al. (2020). Investigation of SARS-CoV-2 variants of concern in England, P.H. England, ed. (Crown), pp. 11.
- Davies, N.G. , Jarvis, C.I. , Edmunds, W.J. , Jewell, N.P. , Diaz-Ordaz, K. , and Keogh, R.H. (2021). Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01. medRxiv.
Cited by
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586
“429 lineage, which forms a single clade (Deng et al., 2021) (Figure 3A; Table S4).”
InfluentialOmicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
Metadata
- Authors
- Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., Reddy, N. P., Sanchez San Martin, C., Federman, S., Cheng, J., Balcerek, J., Taylor, J., Streithorst, J. A., Miller, S., Kumar, G. R., Sreekumar, B., Chen, P.-Y., Schulze-Gahmen, U., Taha, T. Y., Hayashi, J., Simoneau, C. R., McMahon, S., Lidsky, P. V., Xiao, Y., Hemarajata, P., Green, N. M., Espinosa, A., Kath, C., Haw, M., Bell, J., Hacker, J. K., Hanson, C., Wadford, D. A., Anaya, C., Ferguson, D., Lareau, L. F., Frankino, P. A., Shivram, H., Wyman, S. K., Ott, M., Andino, R., & Chiu, C. Y.
- Affiliations
- University of California, San Francisco (US)
- Gladstone Institutes (US)
- California Department of Public Health (US)
- Los Angeles County Department of Public Health (US)
- Monterey County Health Department (US)
- Innovative Genomics Institute (US)
- Corresponding author
- Andino, Raul
- Chiu, Charles Y.
- ORCID
- Deng, Xianding
- Garcia-Knight, Miguel A
- Khalid, Mir M.
- Servellita, Venice
- Wang, Candace
- Morris, Mary Kate
- Sotomayor-González, Alicia
- Glasner, Dustin R
- Reyes, Kevin R
- Federman, Scot
- Cheng, Jing
- Balcerek, Joanna
- Taylor, Jordan
- Miller, Steve
- Kumar, G. Renuka
- Sreekumar, Bharath
- Taha, Taha Y.
- Hayashi, Jennifer
- Simoneau, Camille R.
- McMahon, Sarah
- Lidsky, Peter V.
- Xiao, Yinghong
- Hemarajata, Peera
- Green, Nicole M.
- Bell, John
- Hacker, Jill K.
- Hanson, Carl
- Wadford, Debra A.
- Lareau, Liana F.
- Frankino, Phillip A.
- Shivram, Haridha
- Wyman, Stacia K.
- Andino, Raul
- Chiu, Charles Y.
- Venue
- Cell
- Publisher
- openRxiv
- Published
- 2021-03-09
- Volume
- 184
- Issue
- 13
- Pages
- 3426-3437.e8
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7987058
- OpenAlex
- W3155554970
- Cited by
- 651
- References
- 55
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 59 · 2023: 64 · 2022: 234 · 2021: 257
- FWCI
- 48.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- California Department of Public Health (NU50CK000539)
- Roddenberry Foundation
- Innovative Genomics Institute
- National Institutes of Health (4r33ai120977-03)
- Centers for Disease Control and Prevention (U50CI000498, NU50CK000539, 6NU50CK000539, U01CK000539, NU50CK000498, 6 NU50CK000498)
- University of California, San Francisco
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL105704)
- National Institute on Drug Abuse (DP1DA038043)
- National Institute of Allergy and Infectious Diseases (R33-AI120977, R21AI129455)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, L452R mutation, spike protein mutations, viral transmissibility, viral shedding, antibody neutralization, N501Y mutation, convalescent sera, COVID-19 vaccines, lung organoids, California
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.